Buy Combivent online
Combivent (generic name: Ipratropium/Salbutamol) is a combination preparation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate), bronchodilators used in the management of chronic obstructive pulmonary disease (COPD) and asthma.
Combivent prevents wheezing, difficulty breathing, chest tightness, and coughing in people with chronic obstructive pulmonary disease such as chronic bronchitis (swelling of the air passages that lead to the lungs) and emphysema (damage to the air sacs in the lungs).
Combivent works by relaxing and widening the air passages, which helps you breathe more easily.
Combined bronchodilating medicine.
Ipratropium bromide blocks m-cholinergic receptors of plain muscles of tracheobronchial tree – mostly, large and medium bronchi, – suppresses reflectory bronchoconstriction, and decreases the secretion of respiratory tract’s mucous membrane gland.
With structural similarity to acetylcholine molecule, Ipratropium bromide is its competent antagonist.
The drug effectively prevents the narrowing of bronchi that appears as a result of inhaling cigarette
smoke, cold air, and because of various bronchospasm agents’ action, and eliminates spasm of bronchi
associated with the influence of vagus nerve. The medicine almost doesn’t cause resorptive effect
(weakly affects heart rate and arterial blood pressure – tachycardia requires the inhaling of at leaset 500
doses), only 10% of the drug achieves alveolus and small bronchi, while its remainders accumulate in the
gullet or oral cavity and gets swallowed.
Salbutamol, in therapeutic doses causes evident stimulating action on beta-2-adrenoreceptors of bronchi, blood vessels, and myometrium. It almost doesn’t affect beta-1-adenoreceptors of the heart. The drug inhibits the release of histamine, leukotrienes, and PgD2 and other biologically active substances from mast cells during a long period. It reduces early and late bronchi reactivity. Causes evident broncholytic effect, preventing or arresting bronchospasm, decreases airway resistance, increases lung vital capacity. Positively affects mucociliary clearance (increases it on 36% during chronic bronchitis), stimulates mucus secretion, activates ciliated epithelium functions. Has a wide variety of metabolic effects, such as reduction of K+ in plasma, affecting glycogenolysis and insulin emission, causing hyperglycemic (especially in patients with bronchial asthma) and steatolytic effect, and the increase of acidosis development risk. In recommended therapeutic doses, the drug doesn’t cause negative effect on cardiovascular system and doesn’t increase arterial blood pressure. In the least degree comparing to other medicines of this group causes positive chrono- and inotropic action. The medicine also causes the distention of coronary arteries.
| Quantity | Per item | Price | Order |
|---|---|---|---|
| 1 inhaler | $69.95 | $69.95 |  |
| 3 inhalers | $66.65 | $199.95 | |
